Oncology Voice Network
Join to access to all OVN content. Join for Free
What's Next: Co-creating the next reality for Field Medical after a crisis with Craig Simms
Amplify Consulting Services field medical teams pharma leadership medical value proposition biotech industry insights

What's Next: Co-creating the next reality for Field Medical after a crisis with Craig Simms

  • Apr 28th 2020
  • 40 mins
  • E6

Share This Article

Summary

Today I have Craig Simms, CEO of Amplify Consulting Services and Former MSL Director of Astellas Pharma. Our topic for today is What’s Next: Co-creating the next reality for field medical teams following a global crisis. Really interesting topic, you’re going to enjoy it.

Key Points

  • What Craig is hearing from leaders in pharma, biotech, and medical device companies right now
  • Framework and powerful questions
  • Staying medically relevant, creating value, and value proposition
  • Advice to medical affair leaders in handling moral issues and getting people back to work (once the crisis is over)

Click for Source
Amplify Consulting Services, field medical teams, pharma leadership, medical value proposition, biotech industry insights

Related Topics

Explore the Ecosystem

Meet Our Innovation Partners

You May Also Like

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Apr 8th • 4 mins • read
Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Apr 7th • 12 mins • read
Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

May 6th • 18 mins • read
Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

May 16th • 5 mins • read
Article
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Partner Avatar iNIZIO

Virtual Oncology MSL Team Increases KOL Engagement by 120%

Sep 3rd • 1 min • read
Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Feb 23rd • 8 mins • read

Explore OVN

Articles Expert-written insights
Browse Topics Oncology focus areas
OVN Podcast Flagship show
Community Why join OVN